Free Republic

The findings led to an early halt of a small study comparing Niaspan and Zetia, two compounds commonly used along with statins to reduce heart attack risk ORLANDO, Fla. — Adding a pharmaceutical form of the B vitamin niacin — but not the drug ezetimibe — to a cholesterol-lowering statin drug appears to reduce artery plaque buildup in patients with coronary artery disease, according to much-anticipated results announced at a press conference November 15. The results were from a study that was relatively small — only 208 patients — but provided a head-to-head comparison of niacin and ezetimibe, known by...

When the Food and Drug Administration approved a new type of cholesterol-lowering medicine in 2002, it did so on the basis of a handful of clinical trials covering a total of 3,900 patients. None of the patients took the medicine for more than 12 weeks, and the trials offered no evidence that it had reduced heart attacks or cardiovascular disease, the goal of any cholesterol drug. The lack of evidence has not stopped doctors from heavily prescribing that drug, whether in a stand-alone form sold as Zetia or as a combination medicine called Vytorin. Aided by extensive consumer advertising, sales...

AP Medical Writer Full results of a failed trial on Vytorin, a medicine taken by millions of Americans to lower cholesterol, left doctors stunned that the drug did not improve heart disease even though it worked as intended to lower three key risk factors. Use of Vytorin and a related drug, Zetia, seemed sure to continue to fall after the findings reported Sunday and fresh questions about why drugmakers took nearly two years after the study ended to give results. "A lot of us thought that there would be some glimmer of benefit," said Dr. Roger Blumenthal, a Johns Hopkins...

Correction Appended For decades, the theory that lowering cholesterol is always beneficial has been a core principle of cardiology. It has been accepted by doctors and used by drug makers to win quick approval for new medicines to reduce cholesterol. But now some prominent cardiologists say the results of two recent clinical trials have raised serious questions about that theory — and the value of two widely used cholesterol-lowering medicines, Zetia and its sister drug, Vytorin. Other new cholesterol-fighting drugs, including one that Merck hopes to begin selling this year, may also require closer scrutiny, they say. “The idea that...

New evidence shows that the drug makers Merck and Schering-Plough have conducted several studies of their popular cholesterol medicine Zetia that raise questions about its risks to the liver, but the companies have never published those results. Partial results of the studies, alluded to in documents on the Food and Drug Administration’s Web site, raise questions about whether Zetia can cause liver damage when used long term with other cholesterol drugs called statins. Most of the millions of people who use Zetia take it along with a statin like Lipitor, Crestor or Zocor. Or they take it in a single...

<p>The future of heart disease treatment is coming into focus with a growing emphasis on potent drug cocktails that fight obesity, help smokers quit, ease inflammation and restore a healthy blood-cholesterol balance.</p> <p>The shift may arrive in time for many aging baby boomers, doctors say, with several promising drugs undergoing pivotal tests in humans.</p>